Table 5 Clinical outcome
From: Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity
Dose level | n | Best response | Time on study (months) |
|---|---|---|---|
1 | 8a | PR (5) | 22, 26, 13, 37, 20 |
SD (3) | 6, 5, 4 | ||
2 | 3a | PR (1) | 4 |
SD (2) | 5, 4 | ||
4 | 2a | PR (1) | 26 |
SD (1) | 5 | ||
1(uterine) | SD (1) | 4 | |
1(br) | SD (1) | 4 | |
1(bcc) | SD (1) | 4 | |
5a | 1a | SD (1) | 8 |
1 | SD (1) | 9 | |
5b | 1a | PR (1) | 8 |
2 (cx) | SD (2) | 5, 7 |
All ovarian cancer ( N =19; all DLs) | Intermittent sorafenib (DL 4, 5A, 5B; N =17) |
|---|---|
PR 8/19=42% | PR 2/17 (12%) |
PR or SD⩾ 4 cycles; 15/19=79% | PR or SD⩾ 4 cycles; 10/17 (59%) |
